First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012.
about
Use of Oral Cholera Vaccine and Knowledge, Attitudes, and Practices Regarding Safe Water, Sanitation and Hygiene in a Long-Standing Refugee Camp, Thailand, 2012-2014Deciphering the origin of the 2012 cholera epidemic in Guinea by integrating epidemiological and molecular analyses.Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settingsNeighborhood-targeted and case-triggered use of a single dose of oral cholera vaccine in an urban setting: Feasibility and vaccine coverage.Killed oral cholera vaccines: history, development and implementation challengesPost-licensure deployment of oral cholera vaccines: a systematic review.Mortality Rates during Cholera Epidemic, Haiti, 2010-2011.Cholera Incidence and Mortality in Sub-Saharan African Sites during Multi-country Surveillance.Evaluation of targeted mass cholera vaccination strategies in Bangladesh: a demonstration of a new cost-effectiveness calculator.Use of a cholera rapid diagnostic test during a mass vaccination campaign in response to an epidemic in Guinea, 2012.Oral Cholera Vaccine Coverage, Barriers to Vaccination, and Adverse Events following Vaccination, Haiti, 2013.An Estimation of Private Household Costs to Receive Free Oral Cholera Vaccine in Odisha, India.Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort StudyA Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in EthiopiaAntibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian AdultsOptimal allocation of the limited oral cholera vaccine supply between endemic and epidemic settings.Feasibility and acceptability of oral cholera vaccine mass vaccination campaign in response to an outbreak and floods in MalawiOral Cholera Vaccine Coverage during an Outbreak and Humanitarian Crisis, Iraq, 2015.Management of acute infectious diarrhea for children living in resource-limited settings.Clinical Features of Human Immunodeficiency Virus-Infected Patients Presenting with Cholera in Port-au-Prince, Haiti.Oral cholera vaccine coverage in hard-to-reach fishermen communities after two mass Campaigns, Malawi, 2016.Comparison of school based and supplemental vaccination strategies in the delivery of vaccines to 5-19 year olds in Africa - a systematic review.Implementation research: reactive mass vaccination with single-dose oral cholera vaccine, Zambia.Temporo-spatial dynamics and behavioural patterns of 2012 cholera epidemic in the African mega-city of Conakry, Guinea.Highly targeted cholera vaccination campaigns in urban setting are feasible: The experience in Kalemie, Democratic Republic of Congo.The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships
P2860
Q28354056-45C9539B-8C9C-4BD9-9C64-5807CC60DC52Q30363330-6B90ACCA-8C1F-4E53-A231-814615E3B254Q33552968-4A21FEC7-66D7-4F52-B2BF-E97A96EC2406Q33578033-023A6372-F183-403A-8406-431D354C18D3Q33609586-B5221235-DF71-4059-866E-1FD7C3386DB9Q33817530-24DD09A5-3100-4BBD-864F-40016D42DE58Q34087755-86A91D25-F360-4502-AC4B-0852770F1640Q34456242-526CA15A-51A9-46D8-8CB3-B5786705D57AQ34514555-F9800671-31DC-4249-8D1F-D021F45A245BQ34526917-2C1870E2-AE86-49CE-9AEB-44133E8FE27BQ34640244-FF8E8E03-92DC-46A6-9311-82D7C4B9909AQ34965761-EA6A0689-A13F-448E-AED6-8FE4E4F9E675Q35673478-4F56A60A-97E7-4730-A51C-E846FE27A12FQ35767575-A53E8FBF-8870-4577-8000-55961FE6E3F7Q35880450-6ECF1474-F1A1-4AC5-8A2C-B28AB9FB4507Q36026263-6C26717F-92D4-42ED-ACC2-9630F558F117Q36053849-3BE0F9CE-54CD-4F01-ACEB-203477918388Q36187863-CCC7101B-DD20-4E9C-8EB4-EDE7BD78E76AQ37003932-78885505-4C0F-4EC1-966D-577AFA7355DCQ37524716-D11EBE6A-2E6F-4592-949F-7C5F8E8B5704Q38198766-0CAEBA10-F75D-4949-B9B1-2A0053CDF983Q40469281-363F344C-BA36-4BB3-8207-5277C34F5598Q41298180-3F99EDCC-08FF-451F-8A9E-AEE996E0CA79Q48155181-A9490035-E65F-49A3-8BC7-B10A0C82112BQ48512361-8392206B-AF14-41BA-AC9B-48F6B5170DBEQ49962861-6355B501-5DCE-446F-807A-B7F2C89DE2ABQ54985217-FC7DE247-3C9A-474C-83FF-5A7746A8A9F1Q57481187-59628601-A2E1-4415-BFA6-D226495FBD2A
P2860
First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
First outbreak response using ...... adverse events, Guinea, 2012.
@ast
First outbreak response using ...... adverse events, Guinea, 2012.
@en
type
label
First outbreak response using ...... adverse events, Guinea, 2012.
@ast
First outbreak response using ...... adverse events, Guinea, 2012.
@en
prefLabel
First outbreak response using ...... adverse events, Guinea, 2012.
@ast
First outbreak response using ...... adverse events, Guinea, 2012.
@en
P2093
P2860
P1476
First outbreak response using ...... adverse events, Guinea, 2012.
@en
P2093
Alpha Amadou Dialo
Bala Traore
Christian Itama
Dominique Legros
Francisco J Luquero
Iza Ciglenecki
Keita Sakoba
Lise Grout
Melat Heile
Micaela Serafini
P2860
P356
10.1371/JOURNAL.PNTD.0002465
P407
P577
2013-10-17T00:00:00Z